𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

✍ Scribed by Julia M. Wagner; Björn Hackanson; Michael Lübbert; Manfred Jung

Book ID
107687356
Publisher
Springer-Verlag
Year
2010
Tongue
English
Weight
359 KB
Volume
1
Category
Article
ISSN
1868-7075

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Downregulation of survivin and aurora A
Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy
✍ Anat Biran; Michael Brownstein; Ronit Haklai; Yoel Kloog 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 892 KB

## Abstract Histone deacetylase (HDAC) inhibitors, such as valproic acid (VPA), constitute a novel class of anticancer agents that cause an increase in acetylated histones and thus restore the expression of dormant tumor‐suppressor and other genes related to cell differentiation, cell‐cycle arrest

The use of histone deacetylase inhibitor
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy
✍ Jose A. Karam; Jinhai Fan; Jennifer Stanfield; Edmond Richer; Elie A. Benaim; Eu 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 811 KB

## Abstract The long‐term disease‐free survival in patients with metastatic transitional cell carcinoma (TCC) is still considerably low. Novel chemotherapeutic agents are needed to decrease the morbidity and mortality of TCC. In this study, we have evaluated several epigenetic modifiers for their t